ESTRO 2024 - Abstract Book

S2295

Clinical - Urology

ESTRO 2024

Results:

The main locations of SBRT were bone (n = 63) and adenopathy (n = 39) According to the dose, the most used was the scheme of 18Gy/1fx (n = 33) followed by 30Gy/3fx (n = 19) (Table 1). Most of the patients (54.9%) had high-risk prostate cancer at diagnosis. The primary treatments were external radiotherapy and surgery (47.9% in each case).

As for the diagnosis of metastatic disease, it was diagnosed by PET/CT in 64.8% of patients (54.9% PET/CT-Coline and 9.9% PET/CT-PSMA) and as a metachronous disease (85.9%). 28.2% of patients were castration-resistant.

Two patients (2.8%) developed local progression with a median of 5.50 months. Fourteen patients (19.7%) developed distant disease progression after SBRT (median of 4.4 months). 81.6% of lesions presented radiological response after SBRT. Three deaths occurred, none of them were related to prostate cancer. We found significant variability in the treatment of oligometastatic disease: 14.1% of patients received SBRT alone; 45.1% received SBRT and androgen deprivation therapy (ADT); 40.8% received SBRT, ADT, and a new generation antiandrogen. However, we did not find significant differences according to the treatment selected.